Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Inspira Technologies Oxy B.H.N. Ltd. Warrant (IINNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: IINNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -45.35% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 25248 | Beta 2.07 | 52 Weeks Range 0.17 - 0.99 | Updated Date 04/1/2025 |
52 Weeks Range 0.17 - 0.99 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.67 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -81.03% | Return on Equity (TTM) -219.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 24017559 |
Shares Outstanding - | Shares Floating 24017559 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Inspira Technologies Oxy B.H.N. Ltd. Warrant
Company Overview
History and Background
Inspira Technologies Oxy B.H.N. Ltd. is an Israeli medical device company focused on developing and marketing innovative respiratory support technology. Founded in 2018, it aims to redefine respiratory care with less invasive solutions.
Core Business Areas
- Respiratory Support Systems: Development and commercialization of advanced respiratory support technology, aiming to provide alternatives to traditional mechanical ventilation.
Leadership and Structure
The company has a management team with experience in medical device development and commercialization. The organizational structure is typical of a biotech company with R&D, operations, and commercial departments.
Top Products and Market Share
Key Offerings
- ART (Augmented Respiration Technology) System: Inspira's flagship product is the ART system, a non-invasive respiratory support technology designed to reduce the need for mechanical ventilation. Market share is currently negligible as the product is not yet commercially available. Potential competitors include Medtronic (MDT), Philips (PHG), and Getinge (GETI B).
Market Dynamics
Industry Overview
The respiratory support market is driven by the increasing prevalence of respiratory diseases and the demand for less invasive treatment options. It is a large and growing market.
Positioning
Inspira Technologies aims to disrupt the respiratory support market with its ART system by offering a less invasive and potentially more cost-effective solution than traditional mechanical ventilation.
Total Addressable Market (TAM)
The TAM for respiratory support is estimated to be billions of dollars annually. Inspira is positioned to capture a portion of this market with its innovative technology, primarily targeting patients who may not need full mechanical ventilation.
Upturn SWOT Analysis
Strengths
- Innovative Technology
- Potential for less invasive respiratory support
- Strong Intellectual Property Portfolio
Weaknesses
- Pre-revenue stage
- Reliance on regulatory approvals
- Limited operating history
Opportunities
- Growing respiratory support market
- Partnerships with hospitals and medical centers
- Expansion into new geographic markets
Threats
- Competition from established players
- Regulatory hurdles
- Technological obsolescence
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Philips (PHG)
- Getinge (GETI B.ST)
Competitive Landscape
Inspira Technologies faces stiff competition from established players in the respiratory support market. Its success hinges on the differentiation and effectiveness of its ART system compared to existing technologies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: No historical revenue growth as of this analysis.
Future Projections: Future growth is dependent on the successful commercialization of the ART system and regulatory approvals. Analyst estimates vary widely due to the high-risk nature of the company.
Recent Initiatives: Recent initiatives include clinical trials of the ART system and securing regulatory approvals.
Summary
Inspira Technologies is a high-risk, high-reward investment opportunity. Its innovative ART system holds promise for less invasive respiratory support, but its success depends on regulatory approvals, commercialization, and competition. The company faces significant hurdles, but its technology could disrupt the respiratory support market if effective.
Similar Companies
MDT
Medtronic PLC
MDT
Medtronic PLC
NVCR
Novocure Ltd
NVCR
Novocure Ltd
PHG
Koninklijke Philips NV ADR
PHG
Koninklijke Philips NV ADR
Sources and Disclaimers
Data Sources:
- Company Website
- Press Releases
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be complete or accurate. Investing in early-stage companies involves significant risks, including the potential loss of investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inspira Technologies Oxy B.H.N. Ltd. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-07-14 | Co-Founder, CEO & Director Mr. Dagi Shahar Ben-Noon | ||
Sector Healthcare | Industry Medical Devices | Full time employees 37 | Website https://inspira-technologies.com |
Full time employees 37 | Website https://inspira-technologies.com | ||
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacturing, and marketing of proprietary life support technologies in Israel. Its lead product candidate is INSPIRA ART system, a form of life support designed to provide adaptive blood oxygenation while continuously measuring the patient's blood parameters in real-time. The company has a strategic collaboration with Westchester Medical Center to evaluate INSPIRA ART100 functionality and performance in clinical scenarios. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'anana, Israel.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.